Navigation Links
RNA splicing factor implicated in ovarian tumor cell growth

An RNA-binding protein that is overproduced in ovarian cancer may present a new target for diagnosis or treatment of ovarian and other cancers, according to researchers at the University of Illinois at Chicago.

Researchers in the UIC College of Pharmacy found that interfering with the production of a splicing factor can inhibit the growth and invasiveness of tumor cells in test-tube experiments.

"In a previous study, we observed that human ovarian tumors overexpressed polypyrimidine tract-binding protein, or PTB, and another splicing factor compared to normal matching ovarian tissues," said William Beck, professor and head of biopharmaceutical sciences.

In the new study, Beck and research assistant professor Xiaolong He show that knocking down PTB expression with small, interfering RNA "substantially impairs ovarian tumor cell growth, colony formation and invasiveness."

The research has been published in the online version of the journal Oncogene; it will appear in an upcoming issue of the journal's print version.

Ovarian cancer is commonly referred to as "the silent killer," as it usually is not discovered until its advanced stages. If diagnosed and treated while the cancer is confined to the ovary, the 5-year survival rate is more than 90 percent, according to the American Cancer Society. Unfortunately, only 19 percent of all cases are found in the early stages.

One woman in 58 will develop ovarian cancer during her lifetime, the American Cancer Society said. In 2006, it was estimated that there were 20,180 new cases of ovarian cancer; 15,310 women were expected to die from the disease.

"Ovarian cancer is the deadliest disease among all gynecological cancers," said He. "Two factors account for the dismal mortality outcomes. One is the absence of reliable early detection markers, and the other is inadequacy of present therapy for advanced disease. To improve patient survival, it is critical to iden tify new biomarkers for early detection."

Polypyrimidine tract-binding protein is a key regulator of splicing, Beck said. Defects in pre-messenger RNA splicing have been shown to cause a variety of human diseases. Evidence suggests that altered splicing is associated with and possibly involved in tumor progression or metastasis.

"To the best of our knowledge, this is the first time anyone has shown that interference with the production of a splicing factor can inhibit tumor cell growth and tumor invasiveness," Beck said. "Alternatively-spliced genes and splicing factors are likely to play a key role as therapeutic targets and diagnostic markers in the next decade."


'"/>

Source:University of Illinois at Chicago


Related biology news :

1. RNA splicing occurs in nerve-cell dendrites
2. Protein splicing upsets the DNA colinearity paradigm
3. RNA map provides first comprehensive understanding of alternative splicing
4. Cracking the olfactory code in bees
5. The first impact factor for PLoS Biology ?13.9
6. Open Access journals get impressive impact factors
7. Novel plague virulence factor identified
8. Microreactor efficiently regenerates cofactors for biocatalysis
9. Making plant cells work like miniature factories
10. Studies clarify risk factors for mother-to-child transmission of hepatitis C virus
11. DNA size a crucial factor in genetic mutations, study finds
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/28/2017)... -- News solutions for biometrics, bag drop and New ... At ... 16 March, Materna will present its complete end-to-end passenger journey, ... a real benefit for passengers. To accelerate the whole passenger ... point solutions to take passengers through the complete integrated process ...
(Date:2/26/2017)... DALLAS , Feb. 25, 2017  Securus ... justice technology solutions for public safety, investigation, corrections ... of Recidivism and Reentry. "Too often, ... State prisons and county jails are trying to ... of inmates and friends and family members. While significant ...
(Date:2/21/2017)... PORTLAND, Ore. , Feb. 22, 2017 /PRNewswire/ ... of Companies (Avamere Health Services, Infinity Rehab, Signature Hospice, ... study that will apply the power of IBM cognitive ... and health centers. By analyzing data streaming from sensors ... into physical and environmental conditions, and obtain deeper learnings ...
Breaking Biology News(10 mins):
(Date:3/29/2017)... WuXi Biologics, a leading open-access R&D ... and a WuXi AppTec Affiliate, today announced that ... Excellence Award from IMAPAC, a leading consulting firm. ... recognize outstanding leaders and trend-setters of today, and ... biomanufacturing experts in the industry, along with the ...
(Date:3/29/2017)... 2017  Applied BioMath ( www.appliedbiomath.com ), ... drug research and development, today announced an ... for quantitative systems pharmacology (QSP) support for ... treatment of cancer. Applied ... toxicology studies and first-in-human dose predictions for ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... it is exhibiting in booth 513 at the Association of Community Cancer Centers ... Hotel, March 29-31. , CANCERSCAPE unites key stakeholders from leading national organizations ...
(Date:3/29/2017)... /PRNewswire/ - The University of Missouri Research Reactor (MURR ... Sterigenics International, and General Atomics (GA), announce that MURR,s ... U.S. Nuclear Regulatory Commission (NRC). This marks a critical ... Once operational, production from this facility will be capable ... which currently must be imported from outside ...
Breaking Biology Technology: